Reply to: “Myofibroblast YAP/TAZ is dispensable for liver fibrosis in mice”

We thank Dr. Xu et al. for their insightful letter1 and take advantage of this reply to clarify important aspects of our article,2 in which we employed a well-established mouse model of liver ischemia-reperfusion injury (IRI) to show that activation of YAP attenuated oxidative stress and innate immune responses in liver IRI. As activation of YAP prevented hepatocellular damage in liver IRI, it further mitigated IR-mediated liver fibrosis.
Source: Journal of Hepatology - Category: Gastroenterology Authors: Tags: Letter to the Editor Source Type: research